Application of DNA tetrahedron in preparation of medicine for preventing and / or treating intestinal injury
By using DNA tetrahedron to regulate M2 macrophages and anti-inflammatory signaling pathways, the treatment problem of septic intestinal injury is solved, the intestinal barrier repair and inflammation are achieved, and the intestinal barrier is provided for septic intestinal injury. Effective treatment plan.
Patent Information
- Application Number
- CN202411115559.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-14
- Publication Date
- 2024-11-29
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art lacks effective treatments to reverse intestinal damage caused by sepsis, and intestinal inflammation and barrier dysfunction promote the development of sepsis, and there is a lack of specific treatment options for intestinal damage to sepsis.
DNA tetrahedrons (tFNAs) are used as active ingredients to prepare oral or injectable preparations by regulating the polarization of M2 macrophages and activate anti-inflammatory signaling pathways, combined with pharmaceutically acceptable auxiliary ingredients, for repairing intestinal barriers and reducing Intestinal inflammation.
DNA tetrahedron significantly alleviates LPS-induced intestinal damage, repairs intestinal physical and chemical barriers, regulates macrophage polarization, promotes inflammation repair, and alleviates intestinal damage with sepsis. It has good biocompatibility and permeability through cell membranes activity.
Smart Images

Figure CN119033803A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of nucleic acid molecule drugs, and in particular relates to the use of DNA tetrahedron in preparing drugs for preventing and / or treating intestinal damage. Background Art
[0002] Intestinal damage is the main cause of multi-organ dysfunction in sepsis. Sepsis is a life-threatening multi-organ dysfunction caused by the host's abnormal response to infection. The intestine is the most commonly affected organ in sepsis and is also the initiating organ of multi-organ dysfunction. The intestinal inflammatory storm and barrier damage interact with each other and jointly promote the development of sepsis. Epidemiological studies have shown that intestinal damage in sepsis is significantly correlated with the mortality rate of patients. Inflammatory infection destroys the intestinal barrier structure, and intestinal barrier dysfunction causes bacterial and endotoxin translocation, aggravates intestinal inflammation, and promotes the development of sepsis. Relieving intestinal inflammation and maintaining intestinal barrier function are of great significance to curbing the development of sepsis and reducing the mortality rate of sepsis. At present, there is no effective treatment to reverse intestinal damage in sepsis. We urgently need to develop specific treatment options for intestinal damage in sepsis to inhibit intestinal inflammatory response and repair the intestinal barrier.
[0003] Tetrahedral DNA (TDN), also known as tetrahedral framework nucleic acids (tFNAs), is a new type of DNA nanomaterial based on a tetrahedral structure composed of four DNA single strands. It has good biocompatibility and stability, so it is suitable for clinical application. However, there are currently no reports on the use of DNA tetrahedron in repairing intestinal damage. Summary of the invention
[0004] The purpose of the present invention is to provide the use of DNA tetrahedron in preparing medicine for preventing and / or treating intestinal damage.
[0005] The present invention provides use of DNA tetrahedron in preparing medicine for preventing and / or treating intestinal damage.
[0006] Furthermore, the DNA tetrahedron is composed of four DNA single strands with sequences as shown in SEQ ID NOs. 1 to 4.
[0007] Furthermore, the intestinal injury is colon and / or ileum injury.
[0008] Furthermore, the intestinal injury is septic intestinal injury.
[0009] Sepsis intestinal injury refers to intestinal damage caused by inflammatory infection, which usually leads to destruction of the intestinal barrier structure and dysfunction of the intestinal barrier.
[0010] Furthermore, the drug is a drug for relieving intestinal inflammation.
[0011] Furthermore, the drug is a drug for repairing the intestinal barrier.
[0012] Furthermore, the intestinal barrier is an intestinal physical barrier and / or an intestinal chemical barrier.
[0013] Furthermore, the drug is a drug that promotes the polarization of M2 macrophages.
[0014] Furthermore, the drug is a preparation prepared with DNA tetrahedron as an active ingredient and pharmaceutically acceptable auxiliary ingredients.
[0015] Furthermore, the preparation is an oral preparation or an injection preparation.
[0016] The present invention has achieved the following beneficial effects:
[0017] The tFNAs of the present invention have good cell membrane permeation activity and good biocompatibility, meeting the needs of clinical application.
[0018] The present invention discovered for the first time that tFNAs can alleviate LPS-induced intestinal damage and repair the intestinal physical and chemical barriers; by regulating the aggregation of M2 macrophages in the inflammatory intestinal injury model, it activates anti-inflammatory related signaling pathways, promotes inflammatory repair, and alleviates septic intestinal damage.
[0019] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.
[0020] The above contents of the present invention are further described in detail below through specific implementation methods in the form of examples. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 : PAGE gel image of nucleic acids synthesized by tFNAs; the first lane from left to right is Marker (the band sizes are 20bp, 40bp, 60bp, 80bp, 100bp, 120bp, 140bp, 160bp, 180bp, 200bp, 300bp, 400bp, and 500bp from bottom to top), the second lane is S1, the third lane is S1+S2, the fourth lane is S1+S2+S3, and the fifth lane is tFNAs.
[0022] Figure 2: Capillary electrophoresis of tFNAs; from bottom to top are S1, S2, S3, S4, and tFNAs.
[0023] Figure 3 : tFNAs transmission electron microscopy detection image.
[0024] Figure 4 :The Zeta potential detection result of tFNAs was -6.93mV.
[0025] Figure 5 :The particle size detection result of tFNAs is 11.13nm.
[0026] Figure 6 : Experimental results of tFNAs relieving intestinal inflammation. (A) Animal experiment flow chart, (B) Results of gene expression levels of inflammatory factors in colon tissue, (C) Results of expression levels of inflammatory factors in serum, (D) Results of HE staining of intestinal tissue.
[0027] Figure 7 : tFNAs experimental results of repairing the intestinal barrier. (A) Relative expression of tight junctions in colon tissue, (B) D-lactic acid content in serum, (C) Distribution and relative expression of mucin 2 (MUC-2) in colon tissue, (D) Distribution and relative expression of mucin 2 (MUC-2) in ileum tissue.
[0028] Figure 8 : tFNAs promote the accumulation of M2 macrophages in the colon. (A) Relative expression level of Arg-1 gene in intestinal tissue, (B) Relative quantitative analysis of M1M2 markers in colon tissue, (C) Immunofluorescence staining of M2 macrophages in colon tissue, (D) Immunofluorescence staining of M1 macrophages in colon tissue. DETAILED DESCRIPTION
[0029] The raw materials and equipment used in the present invention are all known products, which are obtained by purchasing commercially available products.
[0030] Example 1. Synthesis and preparation of t-FNA and identification of its physicochemical properties
[0031] 1. Preparation and synthesis:
[0032] Four DNA single strands (S1, S2, S3, S4) were dissolved in TM Buffer (10mM Tris-HCl, 50mM MgCl2, pH=8.0) to a final concentration of 1000nM. The mixture was fully mixed and rapidly heated to 95°C for 10 minutes. The mixture was then rapidly cooled to 4°C and maintained for more than 20 minutes to obtain DNA tetrahedrons, referred to as tFNAs.
[0033] The sequences of the four DNA single strands (5′→3′) are shown in Table 1:
[0034] Table 1. Sequences of four DNA strands (5′→3′)
[0035]
[0036] 2. Identification of physical and chemical properties:
[0037] Experimental methods: 8% polyacrylamide gel electrophoresis (PAGE) was used to detect the synthesis effect. Transmission electron microscopy (TEM) and dynamic light scattering (DLS) were used to measure the particle size of the molecule. Zetasizer Nano ZS90 was used to measure the zeta potential of tFNA molecules.
[0038] Experimental results: The results are as follows Figure 1-5 As shown. Gel electrophoresis and capillary electrophoresis results showed that the molecular weight of the tFNAs band was significantly higher than that of single-stranded DNA and other mixed chains, indicating that the single-stranded DNA was assembled together. Transmission electron microscopy detected particles with a DNA tetrahedral structure, and the zeta potential detected by dynamic light scattering was -6.93mV and the particle size was 11.13nm.
[0039] Example 2: In vivo experiment on tFNAs to alleviate intestinal damage
[0040] 1. Experimental methods
[0041] The intestinal injury caused by sepsis was simulated by intraperitoneal injection of lipopolysaccharide (LPS) into mice. Mice weighing about 20 g were randomly divided into 4 groups: control group (blank control group, intraperitoneal injection of PBS with the same volume as LPS, and tail vein injection of 100 μl of saline), LPS group (model mice, intraperitoneal injection of 5 mg / kg LPS, and tail vein injection of 100 μl of saline), LPS+tFNAs group (experimental group, intraperitoneal injection of 5 mg / kg LPS, and tail vein injection of 100 μl of 250 nM tFNAs), tFNAs group (control group, intraperitoneal injection of PBS with the same volume as LPS, and tail vein injection of 100 μl of 250 nM tFNAs). The mice were killed 6 hours after the model was successfully established, and the colon and ileum samples of the mice were taken for subsequent experiments.
[0042] Serum samples from each group were collected. The supernatant was collected and the changes of M1 (TNF-α, IL-6) and M2 (IL-10) marker inflammatory factors were detected according to the instructions of the enzyme-linked immunosorbent assay (ELISA) kit. Figure 6 b).
[0043] Colon and ileum tissues were taken to extract RNA, and the changes in the gene levels of inflammatory factors such as TNF-α, IL-6, and IL-10 in the tissues were detected (e.g. Figure 6 c).
[0044] Colon and ileum tissues were taken for tissue sections and stained with hematoxylin and eosin to observe the changes in colon and ileum tissue structure (such as Figure 6 d).
[0045] 2. Experimental results
[0046] Histopathological examination revealed that compared with the blank control group, the mucosal layer in the LPS group was severely damaged, disordered, and had obvious congestion and edema, indicating that the animal model of sepsis-induced intestinal injury was successfully established.
[0047] Compared with the LPS group, the relative expression levels of IL-6, IL-1β, and TNF-α mRNA in the tFNAs intervention group were significantly decreased ( Figure 6 bc), indicating that intraperitoneal injection of LPS caused structural damage to the colon and ileum and inflammatory infiltration. Compared with the LPS group, tFNAs treatment significantly reduced tissue damage in the colon and ileum ( Figure 6 d).
[0048] The above results confirmed that tFNAs treatment could alleviate LPS-induced intestinal damage.
[0049] Example 3: tFNAs relieve intestinal inflammation and repair intestinal physical and chemical barriers
[0050] 1. Experimental methods
[0051] Based on the experimental method of Experimental Example 2, the following indicators are further tested:
[0052] Since intestinal inflammation is accompanied by the destruction of the intestinal barrier, in order to verify the expression level of tight junction proteins in intestinal tissue, this experiment used Western blot to detect the expression levels of tight junction proteins ZO-1, occludin, and claudin-1 in the colon and ileum.
[0053] D-lactic acid is an organic acid with low content in normal intestine. Increased D-lactic acid content is an indicator for evaluating increased intestinal permeability. This experiment detected the level of D-lactic acid in serum.
[0054] The chemical barrier is one of the four major intestinal barriers and is composed of chemical substances secreted by the gastrointestinal tract. Mucin (MUC-2) is the main component of the intestinal mucus layer. This experiment used immunohistochemistry to detect the expression and distribution of mucin in the intestine.
[0055] 2. Experimental results
[0056] The results showed that compared with the blank control group, the expression levels of tight junction proteins ZO-1, occludin, and claudin-1 in the LPS group were significantly decreased. After tFNAs treatment, the expression levels of tight junction proteins returned to normal levels, which were significantly higher than those in the LPS group ( Figure 7 a).
[0057] Compared with the blank control group, the level of D-lactic acid in the serum of the LPS group was significantly increased, while tFNAs intervention restored D-lactic acid to normal levels, which was significantly lower than that of the LPS group ( Figure 7 b).
[0058] Immunohistochemistry was used to detect the expression and distribution of mucin in the intestine. Compared with the blank control group, the mucin content in the LPS group was significantly reduced. Compared with the LPS group, tFNAs treatment can significantly promote the secretion of mucin and repair the intestinal chemical barrier ( Figure 7 cd).
[0059] These results indicate that tFNAs treatment can alleviate LPS-induced intestinal inflammation and repair the intestinal physical and chemical barriers.
[0060] Example 4: tFNAs regulate M2 macrophages
[0061] 1. Experimental methods
[0062] Based on the experimental method of Experimental Example 2, the following indicators are further tested:
[0063] In order to study the regulatory effect of DNA tetrahedron on intestinal macrophages, the polarization of intestinal M1 macrophages and M2 macrophages after DNA tetrahedron intervention was evaluated by RT-qPCR and tissue immunofluorescence. In this experiment, total macrophages in colon tissue were labeled with F4 / 80, and M1 macrophage marker CD86 and M2 macrophage marker CD206 were used to co-label M1 macrophages or M2 macrophages, and relative quantification of M1M2 markers was performed.
[0064] 2. Experimental results
[0065] The results of RT-qPCR demonstrated that the gene expression level of Arg-1, a marker of M2 macrophages, decreased in colon and ileum tissues after LPS treatment compared with the blank control group. The expression of Arg-1 was significantly increased after tFNAs treatment compared with the LPS group ( Figure 8 a).
[0066] Tissue immunofluorescence results showed that compared with the blank control group, the number of F4 / 80-positive macrophages in the colon tissue increased after LPS-induced intestinal damage. This is because LPS-induced intestinal damage causes macrophages to be recruited in the submucosal layer of the colon ( Figure 8 c). After tFNAs treatment, the percentage of M2 macrophages with double positive expression of F4 / 80 and CD206 increased significantly, while there was almost no expression of double positive M2 macrophages in the LPS group ( Figure 8 bc). In addition, abundant CD86 and F4 / 80 double-positive M1 macrophages were observed in the LPS group, while few M1 macrophages were observed after tFNAs treatment ( Figure 8 bc).
[0067] The results showed that tFNAs could regulate the polarization of macrophages in the submucosal layer of colonic tissue, promote the aggregation of reparative M2 macrophages, and reduce the aggregation of pro-inflammatory M1 macrophages.
[0068] In summary, the present invention provides a use of a DNA tetrahedron in the preparation of a drug for preventing and / or treating intestinal damage. The present invention first discovered that DNA tetrahedrons can reduce LPS-induced intestinal damage and repair the intestinal physical and chemical barriers; regulate the polarization of macrophages in the submucosal layer of colon tissue, promote the aggregation of repair-type M2 macrophages, reduce the aggregation of pro-inflammatory M1 macrophages, and reduce sepsis intestinal damage. The present invention provides a use of a DNA tetrahedron in the preparation of a drug for preventing and / or treating intestinal damage, which has a very good application prospect.
Claims
1. Use of DNA tetrahedron in the preparation of drugs for preventing and / or treating intestinal damage.
2. The use according to claim 1, characterized in that The DNA tetrahedron is composed of four DNA single strands with sequences as shown in SEQ ID NOs. 1-4.
3. The use according to claim 1, characterized in that The intestinal injury is colon and / or ileum injury.
4. The use according to claim 1, characterized in that The intestinal injury is septic intestinal injury.
5. The use according to any one of claims 1 to 4, characterized in that The drug is a drug that relieves intestinal inflammation.
6. The use according to any one of claims 1 to 4, characterized in that The drug is a drug for repairing the intestinal barrier.
7. The use according to claim 6, characterized in that The intestinal barrier is an intestinal physical barrier and / or an intestinal chemical barrier.
8. The use according to any one of claims 1 to 4, characterized in that The drug is a drug that promotes the polarization of M2 macrophages.
9. The use according to any one of claims 1 to 4, characterized in that The medicine is a preparation prepared by taking DNA tetrahedron as an active ingredient and adding pharmaceutically acceptable auxiliary ingredients.
10. The use according to claim 9, characterized in that The preparation is an oral preparation or an injection preparation.
Citation Information
Patent Citations
Application of DNA tetrahedron in the aspect of improving anti-aging process of cells
CN107961381A
DNA tetrahedron-quercetin compound and application thereof in prevention of sepsis
CN115040657A
Compound for improving Parkinson's disease as well as preparation method and application thereof
CN117653651A
